| Cat.No. | Name | Information |
|---|---|---|
| M1732 | Talazoparib | Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity. |
| M3932 | NVP-TNKS656 | NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM; > 300 fold selectivity against PARP1 and PARP2. |
| M4931 | Rucaparib | Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1, also showing binding affinity to eight other PARP domains. |
| M1664 | AZD2281 (Olaparib) | AZD 2281 (Olaparib, KU-0059436) is a potent PARP (poly ADP-ribose polymerase) inhibitorwith IC50 of 5 and 1 nM for PARP-1and PARP-2 respectively. Olaparib is an autophagy and mitophagy activator. |
| M2215 | Niraparib (MK-4827) | MK-4827 (Niraparib) is a selective PARP1/2 inhibitor with an IC50 value of 3.8 nM/2.1 nM that increases the formation of PARP-DNA complexes through inhibition of PARPase activity, leading to DNA damage, apoptosis, PARP-1-dependent cell death (parthanatos) and cell death. Strong effector activity when acting on cancer cells harboring mutant BRCA-1 and BRCA-2. It is more than 330-fold more selective than PARP3, V-PARP and Tank1. |
| M1785 | 3-Aminobenzamide | 3-Aminobenzamide (PARP-IN-1) is a novel poly(ADP-ribose) polymerase (PARP) inhibitor, and it inhibits cell apoptosis after SCI (Spinal Cord Injury) in caspase-independent way. |
| M13713 | RK-287107 | RK-287107 is a potent and specific tankyrase inhibitor with IC50s of 14.3 and 10.6 nM for tankyrase-1 and tankyrase-2, respectively. RK-287107 blocks colorectal cancer cell growth. |
| M3410 | A-966492 | A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively. |
| M2951 | PJ34 | PJ34 is a PARP inhibitor that also inhibits PARP-1-dependent cell death (parthanatos) with an EC50 of 20 nM, acting with equal effect on PARP1/2. |
| M2831 | ME0328 | ME0328 is a potent and selective PARP inhibitor with IC50 of 0.89 μM for PARP3, about 7-fold selectivity over PARP1. |
| M2587 | JW 55 | JW 55 is an inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2). JW55 decreased auto-PARsylation of TNKS1/2 in vitro with IC50 values of 1.9 uM and 830 nM respectively. |
| M2419 | AZD2461 | AZD-2461 is a potent PARP inhibitor, with IC50s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively. |
| M2056 | PJ34 hydrochloride | PJ34 hydrochloride is the hydrochloride form of PJ34, a PARP inhibitor, and inhibits PARP-1-dependent cell death (parthanatos) with an EC50 of 20 nM, acting equally effectively on PARP1/2. |
| M2010 | BSI-401 | BSI-401 is a novel poly (ADP ribose) polymerase-1 inhibitor. |
| M1972 | Iniparib | Iniparib is an irreversible, noncompetitive inhibitor of PARP1 that disrupts binding between PARP1 and DNA by interacting with the DNA binding domain. |
| M1858 | LT-674 | LT-674 inhibits PARP-1 with an IC50 of 144 nM. |
| M1857 | LT-628 | LT-628 is the racemate of BMN 673 and LT-674. |
| M1645 | AG14361 | AG14361 is a novel poly (ADP-ribose) polymerase-1 inhibitor with a GI50 of 10.9 µM. |
| M1644 | AG-014699 phosphate | AG-014699 (PF-01367338, Rucaparib) is a PARP inhibitor with a Ki of 1.4 nM. |
| M1639 | ABT-888 | ABT-888 (Veliparib) is a potent inhibitor of PARP-1 and PARP-2 with Ki values of 5.2nM and 2.9nM respectively. |
| M56010 | OUL232 | OUL232 is a potent inhibitor of mono-ARTs PARP7, PARP10, PARP11, PARP12, PARP14, and PARP15. |
| M56009 | AZ3391 | AZ3391 is a potent inhibitor of PARP. |
| M56008 | PARP1-IN-5 | PARP1-IN-5 is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). |
| M56007 | DPQ hydrochloride | DPQ hydrochloride (6, 7-dimethoxy-2 -(1-piperazinyl)-4-quinazolinamine hydrochloride) is a PARP1 inhibitor, with IC50 value of 40 nM. |
| M54525 | DSB-1522 | DSB-1522 is a PARP1 inhibitor that can be used in tumor-related studies. |
| M54524 | DM-5167 | DM-5167 is a PARP1 inhibitor that can be used in studies related to triple negative breast cancer. |
| M54523 | NMS-03305293 | NMS-03305293 is a PARP inhibitor with high selectivity for PARP1 isoforms and low DNA capture effect, which specifically kills BRCA mutated tumor cells. In addition, NMS-03305293 can penetrate the blood-brain barrier and can be used in studies related to CNS tumors and brain metastatic tumors. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
